Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies

AAPS Journal

Volumn 18, Issue 1, 2016, Pages 270-280

  Mensing, Sven ^a   Polepally, Akshanth R ^a   König, Denise ^a   Khatri, Amit ^a   Liu, Wei ^a   Podsadecki, Thomas J ^a   Awni, Walid M ^a   Menon, Rajeev M ^a   Dutta, Sandeep ^a  

^a ABBVIE INC   (United States)

Author keywords

2D regimen; 3D regimen; direct acting antiviral; dosing recommendations; population pharmacokinetics

Indexed keywords

CREATININE; CYTOCHROME P450 2C8 INHIBITOR; DASABUVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; ANTIVIRUS AGENT; CYTOCHROME P450 INHIBITOR;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; BOOTSTRAPPING; CREATININE CLEARANCE; DEMOGRAPHY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG FORMULATION; ETHNICITY; FEMALE; GENDER; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MALE; MULTICENTER STUDY (TOPIC); PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION MODEL; POPULATION PHARMACOKINETIC MODEL; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; BIOAVAILABILITY; BIOLOGICAL MODEL; DRUG INTERACTION; GENETICS; HEPACIVIRUS; MEDICINAL CHEMISTRY; METABOLISM; MIDDLE AGED; POPULATION; SEX DIFFERENCE; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CYTOCHROME P-450 ENZYME INHIBITORS; DRUG INTERACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POPULATION; SEX FACTORS; YOUNG ADULT;

EID: 84952984602     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9846-1     Document Type: Article

References (32)

1. Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol. 2014;20(23):7079–88. doi:10.3748/wjg.v20.i23.7079.
2. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65. doi:10.1053/j.gastro.2014.04.045. e1.
3. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–92. doi:10.1056/NEJMoa1402338.
4. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. doi:10.1056/NEJMoa1402869.
5. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603. doi:10.1056/NEJMoa1315722.
6. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–14. doi:10.1056/NEJMoa1401561.
7. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown Jr R, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375–82. doi:10.1056/NEJMoa1408921.
8. Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, et al. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc. 2014;17(4 Suppl 3):19500. doi:10.7448/IAS.17.4.19500.
9. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015. doi:10.1016/S0140-6736(15)60159-3.
10. Sullivan GJ, Rodrigues-Torres M, Lawitz E, Poordad F, Kapoor M, Campbell A, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatol. 2012;56 Suppl 2:S480.
11. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45–53. doi:10.1056/NEJMoa1208809.
12. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222–32. doi:10.1056/NEJMoa1306227.
13. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59(2):979–87. doi:10.1128/AAC.04226-14.
14. Polepally A, Mensing S, Khatri A, Liu W, Awni W, Menon R, et al. Dose- and formulation-dependent non-linear pharmacokinetic model of ABT-450, a protease inhibitor for the treatment of HCV: combined analyses from 12 phase 1 studies. J Pharmacokinet Pharmacodyn. 2014;41(Suppl):S7–S101.
15. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.
16. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; 2015.
17. Copegus (ribavirin) tablets [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; 2013.
18. Rebetol (ribavirin USP) capsules [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2013.
19. Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20–9. doi:10.1016/j.jhep.2015.01.026.
20. Khatri A, Menon RM, Marbury TC, Lawitz EJ, Podsadecki TJ, Mullally VM, et al. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol. 2015;63(4):805–12. doi:10.1016/j.jhep.2015.05.029.
21. Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet. 2015. doi:10.1007/s40262-015-0317-8.
22. Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen). Antimicrob Agents Chemother. 2015. doi:10.1128/AAC.01778-1.
23. Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, et al. Drug-drug interactions of commonly used medications with direct acting antiviral HCV combination therapy of paritaprevir/r, ombitasvir and dasabuvir. Presented at the 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 26–28 May 2015.
24. Viekirax 12.5 mg/75 mg/50 mg film-coated tablets [Summary of product characteristics]. Berkshire, United Kingdom: AbbVie Limited; 2015.
25. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2015. doi:10.1016/j.jhep.2015.10.005.
26. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. 2006;62(6):710–4. doi:10.1111/j.1365-2125.2006.02704.x.
27. Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J. 2012;14(3):571–80. doi:10.1208/s12248-012-9368-z.
28. Gupta SK, Kantesaria B, Glue P. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discov Ther. 2013;7(4):158–63.
29. Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57(12):6097–105. doi:10.1128/AAC.00608-13.
30. Gupta SK, Kantesaria B, Glue P. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Drug Discov Ther. 2014;8(2):89–95.
31. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9. doi:10.1053/j.gastro.2010.04.013. e18.
32. Khatri A, Dutta S, Marbury T, Preston RA, Rodrigues L, Wang H, et al. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. Boston: 65th Annual Meeting of the American Association for the Study of Liver Diseases; 2014.